@xconomy.com 4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
@techcrunch.com 7 years ago
Crunch Report | Judge Rules CRISPR-Cas9 Belongs to Broad Institute
@techcrunch.com 7 years ago
Judge rules CRISPR-Cas9 patents belong to Broad Institute of Harvard and MIT
@theverge.com 7 years ago
CRISPR patents, potentially worth billions, belong to Broad Institute